A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer | NYU Langone Health

Go Back to All Clinical Trials

A Phase 2 Randomized Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Previously Untreated Patients With Metastatic Triple-negative Breast Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Tumor must be PD-L1- negative. 2) Adequate Laboratory measurements, blood counts – per protocol. 3) Measurable disease according to RECIST, version 1.1.

You may not be eligible for this study if the following are true:

1) Active central nervous system (CNS) disease. 2) History of hemolytic anemia, autoimmune thrombocytopenia in the last 3 months. 3) Prior chemotherapy for metastatic disease.